Industry News
Biotechnology Industry News
Immuneering has reported updated…
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival at 12 months.
Ventyx has achieved its goal of…
Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.
Parabilis is taking an early lead…
Parabilis is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a push for its potential first-in-class cancer drug.
Attempting to scry the future of…
Attempting to scry the future of the pharmaceutical industry, professional services juggernaut PwC has laid out lofty ambitions for what it believes drugmakers could achieve by 2035—as well as the steps those companies should take
Shortly after securing a…
Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer treatments via a pact that could be worth up to $950 million.
With a $125 million series B…
With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class rare disease drug, DIAG723.
Servier is committing to rare…
Servier is committing to rare neurology for the long term, using focused science and strategic collaborations to bring new options to patients in need
The show is over for Pulmocide’s…
The show is over for Pulmocide’s phase 3 trial after patients given its investigational inhaled antifungal had lower response rates and a higher chance of death than patients in the control arm.
Amgen is getting down with Disco…
Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a target the biotech has already identified.
Rakuten Medical has added to its…
Rakuten Medical has added to its tally of mega-rounds, pocketing another $100 million to push its lead light-based cancer therapy toward a targeted FDA approval filing in 2028.
Soley Therapeutics has secured…
Soley Therapeutics has secured $200 million in series C funds, which the AI-enabled biotech plans to use to take its lead acute myeloid leukemia asset into the clinic.
Basilea Pharmaceutica is…
Basilea Pharmaceutica is continuing its quest to develop much-needed new antifungal drugs by penning a deal with Prokaryotics worth at least $48 million.
GSK’s potential “functional…
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.
A phase 3 trial of Hutchmed’s…
A phase 3 trial of Hutchmed’s autoimmune disease candidate sovleplenib has hit its primary endpoint, delivering a boost to an asset that was held up by quality issues in another indication.
Alveus Therapeutics, which…
Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.
Bright Minds Biosciences has…
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a jolt and setting up future registrational trials for the serotonin receptor agonist.
Boehringer Ingelheim has unveiled…
Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a deal worth potentially $120 million with genomics-focused Variant Bio.
Amgen is adding Dark Blue to its…
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its organization.
In a strategic move that could…
In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics.
Eli Lilly has returned to Nimbus…
Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot space of oral obesity therapies.